Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Oct 14:10:129.
doi: 10.1186/1476-4598-10-129.

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation

Affiliations

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation

Ramesh Ummanni et al. Mol Cancer. .

Abstract

Background: We have previously reported significant downregulation of ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) in prostate cancer (PCa) compared to the surrounding benign tissue. UCHL1 plays an important role in ubiquitin system and different cellular processes such as cell proliferation and differentiation. We now show that the underlying mechanism of UCHL1 downregulation in PCa is linked to its promoter hypermethylation. Furthermore, we present evidences that UCHL1 expression can affect the behavior of prostate cancer cells in different ways.

Results: Methylation specific PCR analysis results showed a highly methylated promoter region for UCHL1 in 90% (18/20) of tumor tissue compared to 15% (3/20) of normal tissues from PCa patients. Pyrosequencing results confirmed a mean methylation of 41.4% in PCa whereas only 8.6% in normal tissues. To conduct functional analysis of UCHL1 in PCa, UCHL1 is overexpressed in LNCaP cells whose UCHL1 expression is normally suppressed by promoter methylation and found that UCHL1 has the ability to decrease the rate of cell proliferation and suppresses anchorage-independent growth of these cells. In further analysis, we found evidence that exogenous expression of UCHL1 suppress LNCaP cells growth probably via p53-mediated inhibition of Akt/PKB phosphorylation and also via accumulation of p27kip1 a cyclin dependant kinase inhibitor of cell cycle regulating proteins. Notably, we also observed that exogenous expression of UCHL1 induced a senescent phenotype that was detected by using the SA-ß-gal assay and might be due to increased p14ARF, p53, p27kip1 and decreased MDM2.

Conclusion: From these results, we propose that UCHL1 downregulation via promoter hypermethylation plays an important role in various molecular aspects of PCa biology, such as morphological diversification and regulation of proliferation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
UCHL1 protein and mRNA expression in prostate cancer. (A) UCHL1 is downregulated in 32 out of 40 PCa patients. A representative Western blot was shown here. GAPDH is used as an internal loading control. (B) Quantitative RT-PCR of UCHL1 transcripts from prostate cancer tissue and normal prostate tissues. The ratio of UCHL1 expression was normalized against GAPDH expression and is graphically presented as box plots (t-test was used to analyze statistical significance).
Figure 2
Figure 2
UCHL1 expression is regulated by promoter methylation in PCa. (A) MSP results show highly (44, 45, 48 and 51) and weakly (49) methylated tumour samples as well as positive (M) and negative (U) controls. The M lane shows amplification with primers specific for methylated CpG sites and the U lane with primers specific for unmethylated CpG sites. The positive control is obtained from in vitro methylated DNA and the negative control from peripheral blood of a healthy donor. (B) The pyrogramm of one sample covers 12 CpG sites (grey bars) in the promoter region of UCHL1 with a methylation rate between 35 and 55% (mean 48%). Nucleotides confirming complete bisulfite conversion are shown in yellow bars. (C) The pyrosequencing of 20 normal and 20 prostate cancer samples revealed a significant higher rate of methylation for the cancer tissue. 18 tumour samples show a methylation density in the promoter region of UCHL1 clearly higher than the normal prostate tissue.
Figure 3
Figure 3
UCHL1 expression in wild type and stably transfected prostate cancer cell lines. UCHL1 mRNA (upper panel) and protein (lower panel) are abundantly expressed in DU145, while LNCaP cells show an absence of UCHL1 expression. The housekeeping gene RPLP0 for RT-PCR and GAPDH for Western blotting confirm equivalent loading of samples. Exogenous stable expression of UCHL1 is obtained in androgen dependant prostate cancer cells (LNCaP) by retroviral transduction. For confirmation of expression of UCHL1 mRNA and protein, RT-PCR (upper panel) and Western blotting (lower panel) were performed respectively.
Figure 4
Figure 4
Influence of UCHL1 overexpression on the phenotype of LNCaP cells. (A) Cell proliferation after overexpression of UCHL1 and cell viability was measured by using Vi-CELL Cell Viability Analyzer. (B) Colony formation assay in soft agar for LNCaP cells with (UCHL1) or without UCHL1 (Puro) expression. UCHL1 positive cells (top) show significant suppression in the number of colonies appearing in soft agar and in the colony morphology compared to mock cells (bottom). (C) After crystal violet staining the number of colonies appearing on soft agar plates was counted using an invert microscope and the results are expressed as mean ± SD of 3 independent experiments (p < 0.005). (D) Senescence was quantified using SA-ß-gal-staining. (E) Number of SA-ß-gal positive cells was counted using an Axioplan microscope and the results are depicted as mean ± SD of 3 independent experiments.
Figure 5
Figure 5
In LNCaP cells exogenous expression of UCHL1 influences K63 ubiquitylation. (A) Representative Western blots against mono- and polyubiquitin from LNCaP cells stably expressing UCHL1 or empty vector as control. GAPDH is used as an internal housekeeping protein to ensure equal loading of samples. (B) Measurement of chymotrypsin like activity of the proteasome in UCHL1 positive or mock LNCaP cells served as control. The results are expressed as the mean ± SD from 3 independent experiments each in triplicates. (C) UCHL1 overexpression in LNCaP cells reduces the level of K63 chain specific ubiquitylated proteins detected by Western blotting with anti K63 linked polyubiquitin antibody. GAPDH is used as loading control.
Figure 6
Figure 6
UCHL1 suppresses anchorage-independent growth and cell proliferation via AKT phosphorylation and stabilization of p53 levels. (A) Representative Western blots showing decreased levels of phospho AKT in UCHL1 positive LNCaP cells. Furthermore, accumulation of p53, decreased MDM2 levels and an increase in p14ARF without any influence on p21 was shown by Western blot. β-Actin was used as controls to ensure equal loading of samples. (B-C) Quantitative RT-PCR revealed no changes of p53 and MDM2 mRNA levels in UCHL1 positive cells. The results are indicated as mean ± SD of 3 independent experiments.
Figure 7
Figure 7
Effects of overexpression of UCHL1 on the expression of cell cycle related proteins. (A) Representative Western blots against UCHL1, p27Kip1, Cyclin A and β-actin, as a house keeping protein, demonstrated that UCHL1 induces accumulation of p27Kip1 and reduction of Cyclin A expression in LNCaP cells. (B-C) Quantitative RTPCR revealed no statistically significant change of p27Kip1 and Cyclin A mRNA level in UCHL1 positive cells. The results are indicated as mean ± SD of 3 independent experiments. (D) Protein levels of Rb, pRb, Cyclin E, Cyclin D and β-actin were detected by Western blotting analyses using corresponding antibodies in UCHL1 overexpressing LNCaP cells. (E) Quantitative RTPCR revealed no statistically significant change of Cyclin D mRNA level in UCHL1 positive cells. The results are indicated as mean ± SD of 3 independent experiments.

Similar articles

Cited by

References

    1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8–31. doi: 10.3322/canjclin.49.1.8. 1. - DOI - PubMed
    1. Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388–1413. doi: 10.2741/1891. - DOI - PubMed
    1. Ummanni R, Mundt F, Pospisil H, Venz S, Scharf C, Barett C, Falth M, Kollermann J, Walther R, Schlomm T. et al.Identification of Clinically Relevant Protein Targets in Prostate Cancer with 2D-DIGE Coupled Mass Spectrometry and Systems Biology Network Platform. PLoS One. 2011;6:e16833. doi: 10.1371/journal.pone.0016833. - DOI - PMC - PubMed
    1. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005;6:599–609. doi: 10.1038/nrm1700. - DOI - PubMed
    1. Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009;78:363–397. doi: 10.1146/annurev.biochem.78.082307.091526. - DOI - PMC - PubMed

Publication types

MeSH terms